Diabetic kidney disease (DKD) has emerged as one of the deadliest complications of diabetes, affecting millions globally and driving poor outcomes. Its development reflects a complex interplay of multiple mechanisms that together cause progressive kidney damage. As a result, DKD has become the leading cause of both CKD and ESKD.1 DKD is clinically defined as diabetes with either persistent (>3 months) eGFR 300 mg/d or spot urine albumin to creatinine ratio >0.3).2 The presence and degree of albuminuria are robust predictors of progressive kidney function decline and mortality and have long served as a primary therapeutic target.2 The prevalence of nonproteinuric DKD is rising, complicating diagnosis and management. Traditional markers, such as albuminuria and eGFR, often miss early kidney damage, and many patients initially exhibit hyperfiltration. Kidney biopsy, though definitive, is typically reserved for suspected nondiabetic disease, limiting its broader use. These gaps underscore the challenge of detecting DKD early and understanding its complex pathogenesis, both crucial for developing more effective therapies. DKD exemplifies gene–environment interplay, with genetic influences shaping disease susceptibility. Studies, including the GEnetics of Nephropathy: an International Effort consortium Genome-Wide Association Study in type 1 diabetes,3 have identified loci, such as AFF3, ERBB4, and COL4A3, implicating pathways of fibrosis, renal signaling, and glomerular structure. Despite these insights, management remains focused on controlling glucose and BP, with renin-angiotensin system inhibition as the cornerstone, while newer agents such as sodium-glucose transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists, offer additional protection, mainly in proteinuric DKD.2 These findings highlight that while therapies slow progression, a deeper understanding of DKD's genetic and metabolic complexity is essential to develop truly transformative treatments. While genetic studies have identified loci associated with DKD risk, its pathogenesis is driven by multiple overlapping processes that alter renal cellular function and structure (Figure 1). Elevated intracellular glucose saturates glycolysis, diverting carbon into the polyol, advanced glycation end products, protein kinase C, and hexosamine pathways.4 These pathways increase oxidative stress, disrupt redox balance, and alter gene expression, ultimately causing mitochondrial dysfunction and activating profibrotic genes.4 Persistent protein kinase C activation in glomerular endothelial cells increases vascular endothelial growth factor-A and endothelin-1, disrupting the filtration barrier and promoting albumin leakage.4 In response to advanced glycation end products, mesangial cells upregulate tumor growth factor-β and connective tissue growth factor, leading to excessive extracellular matrix deposition and glomerulosclerosis.4 Meanwhile, reactive oxygen species accumulate in renal cells, inducing chemokine production that recruits inflammatory cells perpetuating a cycle of inflammation and fibrosis.5 These interconnected metabolic, oxidative, and inflammatory pathways form a self-amplifying cycle of kidney injury, illustrating the complexity of DKD and representing just a subset of described cellular mechanisms.Figure 1: Effects of hyperglycemia on metabolism and nephron function. (1) Increased glucose filtered by the glomerulus damages the filtration barrier, leading to albumin leakage. (2) Filtered glucose is reabsorbed in proximal tubular cells through the SGLT2 with Na+, raising intracellular glucose that is shunted into the AGEs, protein kinase C, hexosamine, and polyol pathways, driving oxidative stress and inflammation. Excess glucose also causes mitochondrial dysfunction, impaired β-oxidation, and fatty acid accumulation, inducing ROS and reactive aldehydes. These effects are amplified by albumin reabsorption through megalin/cubilin and decreased AKR1A1, leading to tubular injury and fibrosis. SGLT2 inhibitors block glucose reabsorption, while GLP-1 receptor agonists act through multiple mechanisms, including reducing inflammation. (3) Reduced Na+ delivery to the macula densa activates the RAS using the juxtaglomerular apparatus, causing efferent arteriole constriction and glomerular hyperfiltration, further increasing albumin and glucose filtration. RAS inhibitors counteract this effect. (4) MR activation in the distal and collecting tubules increases Na+ and water reabsorption, causing hypertension that worsens albumin filtration which is blocked by MR antagonists. Created in BioRender. https://BioRender.com/l8bjg8g. AGE, advanced glycation end product; GLP-1, glucagon-like peptide 1; MR, mineralocorticoid receptor; RAS, renin-angiotensin system; ROS, reactive oxygen species; SGLT2, sodium-glucose transporter 2.Hyperglycemia not only disrupts renal cell biology but also reshapes kidney structure and function, advancing DKD at the organ level. In early stages, hyperglycemia reduces sodium delivery to the distal nephron, activating the renin-angiotensin system and driving efferent arteriolar constriction, hyperfiltration, glomerular enlargement, and subsequent injury4 (Figure 1). This hyperfiltration state promotes podocyte hypertrophy through growth factor pathways, destabilizing structure and adhesion, leading to foot process effacement and proteinuria.4 Downstream of these glomerular changes, albumin internalization through megalin and cubilin, together with uptake of oxidized lipids through kidney injury molecule-1, intensifies tubular injury and accelerates disease progression.4 Mineralocorticoids regulate sodium reabsorption in collecting tubules, contributing to hypertension, and directly influence inflammation and fibrosis.6 Although therapies targeting hyperglycemia, intraglomerular hemodynamics, or mineralocorticoid signaling can slow DKD progression, they do not halt it, suggesting that metabolic memory and other pathways contribute to disease. Alongside hyperglycemia, impaired fatty acid metabolism in proximal tubules contributes to diabetic kidney injury. These cells rely primarily on fatty acids for energy, and diabetes-induced defects in this pathway reduce ATP availability, impair sodium–potassium ATPase activity, and disrupt nutrient/electrolyte transport.7 In preclinical models, pharmacological activation of fatty acid oxidation restores energy homeostasis, improves tubular function, and protects against fibrosis.8 In humans, fenofibrate, a peroxisome proliferator–activated receptor agonist, has demonstrated renoprotective effects in clinical trials, lowering albuminuria and slowing kidney function decline.9 This represents an example of how investigating elevated glucose and impaired fatty acid metabolism as joint drivers of kidney injury could reveal actionable biomarkers and novel therapeutic targets in DKD. In this issue, Ma et al.10 identified AKR1A1 as a promising candidate biomarker that links dysregulated fatty acid metabolism with kidney function decline in DKD. AKR1A1, a proximal tubule detoxification enzyme, protects against lipid-derived aldehyde stress. In vitro, loss of AKR1A1 rendered proximal tubule cells more vulnerable to lipid-induced toxicity, underscoring its role in maintaining tubular health. Clinically, higher circulating AKR1A1 levels in Black Americans with type 2 diabetes were associated with slower eGFR decline, independent of LDL cholesterol and apolipoprotein L1 risk variants. Together, these findings highlight AKR1A1 as both a potential biomarker of metabolic stress and a therapeutic target in early DKD. Many challenges in translating AKR1A1 to clinical practice mirror those faced across translational research. While AKR1A1 is a promising advance, in vitro models cannot fully capture kidney complexity, underscoring the need for validation in human tissue. Reliance on a single AKR1A1 measure may overlook dynamic changes with interventions in lipid, glycemic, or BP control, common in DKD management. Clinical studies often use eGFR slope, a relevant but continuous outcome, rather than hard end points like ESKD or mortality, complicating biomarker translation. While inclusion of a Black American cohort helps address the predominance of European ancestry in research, validation in multiancestry cohorts would enhance generalizability and clinical utility. Despite these constraints, the study illustrates how translational research can yield actionable biomarkers and therapeutic targets in kidney disease. Even amidst the inherent challenges of translational research, the study by Ma et al.10 exemplifies how targeted biomarker investigations can advance translational nephrology. By integrating genome-wide association data, proteomics, and functional in vitro assays, the study provides a potential mechanistic link between genetic variants and protein-level effects. Functional knockout experiments in proximal tubule cells, exposed to high glucose and the fatty acid, palmitate, to emulate diabetic stress, suggest a causal relationship between AKR1A1 and renal cell viability. Furthermore, adjustment for key covariates, including APOL1 genotype, LDL cholesterol, and others strengthens the study's translational relevance to patients with DKD. Finally, while eGFR slope is not a hard clinical end point, its use enhances the clinical significance of the findings by relating AKR1A1 to meaningful changes in kidney function over time. Efforts like this provide a valuable starting point for bridging the gap between molecular discovery and clinical application, highlighting the promise of translational research to inform patient care. The discovery of AKR1A1 highlights the potential for molecular biomarkers to transform clinical nephrology, offering new strategies for identifying and managing early kidney injury. Measurement of AKR1A1 could help identify patients at risk for DKD progression earlier than standard markers like albuminuria. By linking metabolic stress in proximal tubules to measurable circulating protein levels, this work provides a potential avenue for precision risk stratification and individualized intervention. Furthermore, the protective role of AKR1A1 suggests that modulating its activity could become a therapeutic strategy to slow kidney function decline. DKD is the leading cause of CKD and ESKD worldwide, affecting millions of people with diabetes. It exemplifies the convergence of genetic susceptibility and diverse pathogenic mechanisms, and although current therapies can slow disease progression, they cannot fully prevent it. This highlights the urgent need for reliable biomarkers that enable earlier detection of DKD beyond albuminuria and identify new therapeutic targets. Despite the challenges of translational research, integrating genetics, proteomics, metabolomics, and transcriptomics at the cellular and organ level offers a powerful opportunity to improve DKD diagnosis, management, and patient outcomes.
Leon et al. (Thu,) studied this question.